Epix rises on enrolment expectations for stroke agent trial
This article was originally published in Clinica
Executive Summary
The share price of troubled Epix Pharmaceuticals rose last week, after the firm revealed that enrolment in a clinical trial of its MRI-based imaging agent for stroke was scheduled for completion earlier than expected.